Sec Form 4 Filing - GHALIE RICHARD G @ MEI Pharma, Inc. - 2021-07-01

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person GHALIE RICHARD G 2. Issuer Name and Ticker or Trading Symbol MEI Pharma, Inc. [ MEIP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Medical Officer (Last) (First) (Middle) C/O MEI PHARMA, INC., 11455 EL CAMINO REAL, SUITE 250 3. Date of Earliest Transaction (MM/DD/YY) 07/01/2021 (Street) SAN DIEGO, CA92130 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 2.95 07/01/2021 A 320,000 ( 1 ) 07/01/2031 Common Stock 320,000 $ 0 320,000 D Stock Option (Right to Buy) $ 1.21 ( 2 ) 03/07/2026 Common Stock 130,000 130,000 D Stock Option (Right to Buy) $ 1.38 ( 2 ) 07/14/2026 Common Stock 25,000 25,000 D Stock Option (Right to Buy) $ 2.88 ( 3 ) 07/07/2027 Common Stock 65,000 65,000 D Stock Option (Right to Buy) $ 4.28 ( 4 ) 07/12/2028 Common Stock 130,000 130,000 D Stock Option (Right to Buy) $ 2.52 ( 5 ) 07/01/2029 Common Stock 150,000 150,000 D Stock Option (Right to Buy) $ 3.49 ( 6 ) 07/02/2030 Common Stock 150,000 150,000 D Stock Option (Right to Buy) $ 3.55 ( 7 ) 05/03/2031 Common Stock 75,000 75,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other GHALIE RICHARD G C/O MEI PHARMA, INC. 11455 EL CAMINO REAL, SUITE 250 SAN DIEGO, CA92130 Chief Medical Officer Signatures /s/ Brian G. Drazba, as attorney in fact 07/06/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )One-quarter of such options shall vest on July 1, 2022, and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2022. ( 2 )All options are currently exercisable. ( 3 )One-quarter of such options vested on July 7, 2018, and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 7, 2018. ( 4 )One-quarter of such options vested on July 12, 2019, and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 12, 2019. ( 5 )One-quarter of such options vested on July 1, 2020, and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2020. ( 6 )One-quarter of such options vested on July 2, 2021, and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 2, 2021. ( 7 )One-quarter of such options shall vest on May 3, 2022, and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on May 3, 2022.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.